HeartFlow (HTFL) Stock Overview
A medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
HTFL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
HeartFlow, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.15 |
| 52 Week High | US$41.22 |
| 52 Week Low | US$20.13 |
| Beta | 0 |
| 1 Month Change | -8.08% |
| 3 Month Change | -3.43% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.04% |
Recent News & Updates
HeartFlow: Finding Its Flow, Outpacing Guidance
Summary HeartFlow delivered a strong Q1 with 41% revenue growth and gross margins above 80%, outpacing prior guidance. HTFL raised full-year sales guidance to $228–$232 million, with management likely guiding conservatively given ongoing account growth and market share gains. Despite solid fundamentals and AI-driven efficiencies, operating leverage remains limited due to elevated R&D spending, though future margin expansion is expected. Shares have surged 40% since March, now trading at ~12x sales; the current valuation tempers my enthusiasm for adding at these levels. Read the full article on Seeking Alpha
HTFL: Beat And Raise Performance Will Face Sector Pressure Ahead
HeartFlow's analyst price target has moved to $37.00, with analysts citing the recent Q1 sales beat, raised full year sales guidance, and sector multiple shifts as key drivers of the updated fair value inputs. Analyst Commentary Analysts covering HeartFlow are updating their views around the new US$37.00 price target, focusing on how recent results and sector moves affect valuation, execution risk, and future growth potential.Recent updates
HeartFlow: Finding Its Flow, Outpacing Guidance
Summary HeartFlow delivered a strong Q1 with 41% revenue growth and gross margins above 80%, outpacing prior guidance. HTFL raised full-year sales guidance to $228–$232 million, with management likely guiding conservatively given ongoing account growth and market share gains. Despite solid fundamentals and AI-driven efficiencies, operating leverage remains limited due to elevated R&D spending, though future margin expansion is expected. Shares have surged 40% since March, now trading at ~12x sales; the current valuation tempers my enthusiasm for adding at these levels. Read the full article on Seeking AlphaHTFL: Beat And Raise Performance Will Face Sector Pressure Ahead
HeartFlow's analyst price target has moved to $37.00, with analysts citing the recent Q1 sales beat, raised full year sales guidance, and sector multiple shifts as key drivers of the updated fair value inputs. Analyst Commentary Analysts covering HeartFlow are updating their views around the new US$37.00 price target, focusing on how recent results and sector moves affect valuation, execution risk, and future growth potential.Companies Like HeartFlow (NASDAQ:HTFL) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Shareholder Returns
| HTFL | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | -14.8% | 7.5% | -0.7% |
| 1Y | n/a | -36.1% | 20.3% |
Return vs Industry: Insufficient data to determine how HTFL performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how HTFL performed against the US Market.
Price Volatility
| HTFL volatility | |
|---|---|
| HTFL Average Weekly Movement | 9.9% |
| Healthcare Services Industry Average Movement | 9.8% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HTFL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HTFL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 843 | John Farquhar | www.heartflow.com |
HeartFlow, Inc., a medical technology company, provides non-invasive solutions for diagnosing and managing coronary artery diseases the United States and worldwide. Its HeartFlow Platform uses AI and computational fluid dynamics to creates a personalized 3D model of a patient’s heart from a single coronary computed tomography angiography, a specialized type of scan that provides detailed images of the heart’s arteries. The company provides Heartflow RoadMap Analysis that offers an intuitive anatomic visualization of the coronary arteries; Heartflow FFRCT Analysis, which calculates blood flow and pinpoints clinically; and Heartflow Plaque Analysis that provides a comprehensive assessment of coronary plaque, enabling optimized medical treatment strategies.
HeartFlow, Inc. Fundamentals Summary
| HTFL fundamental statistics | |
|---|---|
| Market cap | US$2.35b |
| Earnings (TTM) | -US$111.83m |
| Revenue (TTM) | US$191.42m |
Is HTFL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HTFL income statement (TTM) | |
|---|---|
| Revenue | US$191.42m |
| Cost of Revenue | US$42.00m |
| Gross Profit | US$149.42m |
| Other Expenses | US$261.25m |
| Earnings | -US$111.83m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 78.06% |
| Net Profit Margin | -58.42% |
| Debt/Equity Ratio | 0% |
How did HTFL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 21:49 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
HeartFlow, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Plovanic | Canaccord Genuity |
| Eugene Mannheimer | Freedom Capital Markets |
| Robert Marcus | J.P. Morgan |